Preclinical proof of principle for orally delivered Th17 antagonist miniproteinsDe novo proteins can be computationally designed with sub-picomolar affinity and extreme stability to enable oral administration and were effective in a model of colitis.De novo proteins can be computationally designed with sub-picomolar affinity and extreme stability to enable oral administration and were effective in a model of colitis.Stephanie Berger, Franziska Seeger, Ta-Yi Yu, Merve Aydin, Huilin Yang, Daniel Rosenblum, Laure Guenin-Macé, Caleb Glassman, Lauren Arguinchona, Catherine Sniezek, Alyssa Blackstone, Lauren Carter, Rashmi Ravichandran, Maggie Ahlrichs, Michael Murphy, Ingrid Swanson Pultz, Alex Kang, Asim K. Bera, Lance Stewart, K. Christopher Garcia, Shruti Naik, Jamie B. Spangler, Florian Beigel, Matthias Siebeck, Roswitha Gropp, David Bakerhttps://www.cell.com/cell/fulltext/S0092-8674(24)00631-7?rss=yeshttp://www.cell.com/cell/inpress.rssCellCell RSS feed.Wireless News CampaignJune 27, 2024

Powered by WPeMatico